Pharma & Biotech - Page 4

AstraZeneca (AZN) and Daiichi Sankyo are facing a significant obstacle in their push to expand the use of cancer drug Enhertu into a key new treatment setting. The two pharmaceutical giants have

Akeso and Summit Therapeutics (SMMT) have reported a significant breakthrough in the treatment of non-small cell lung cancer with their jointly developed drug ivonescimab. The bispecific antibody reduced the risk of death

Samsung Biologics has landed a new biologics manufacturing contract worth $262 million with an unnamed European pharmaceutical company, according to a securities filing. The deal, disclosed on Thursday, will run through the

Sanofi is turning to one of the fastest-growing sports in the country to drive awareness of its protein-based COVID-19 vaccine, Nuvaxovid. The French pharmaceutical giant has announced a partnership with USA Pickleball,

The full phase 3 dataset from Merck (MRK) and Gilead’s (GILD) failed Trodelvy trial in first-line non-small cell lung cancer has now been made public, raising significant questions for the industry. The

AstraZeneca’s (AZN) camizestrant, branded Etcamah, has failed to demonstrate a statistically significant improvement in a major Phase III breast cancer trial, dealing a blow to the drug’s broader commercial ambitions. The SERENA-4

Cencora’s Ameer Ali is sending a clear message to pharmaceutical supply chain stakeholders: the time to begin planning for the shift to NDC-12 is right now. Ali, senior director of manufacturer operations

A major Novartis investor has publicly called for sweeping board-level changes at the Swiss pharmaceutical giant following two consecutive clinical trial failures. David Samra, managing director at Artisan Partners and a founding

Pharmaceutical pricing policy in the United States has become increasingly difficult to navigate for drug and biotech companies operating across global markets. President Donald Trump’s ongoing deals with pharmaceutical companies, combined with

Argonaut Manufacturing Services has completed the sale of its Life Sciences and Diagnostics division to 1315 Capital, a Philadelphia-based healthcare-focused private equity firm. The divested division will now operate as an independent